文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

COVID-19大流行期间合并SARS-CoV-2感染的癌症患者治疗连续性的种族与民族不平等

Racial and Ethnic Inequities in Cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2.
PubMed 文献 · JAMA Netw Open · 2024-05-01
一句话结论在合并SARS-CoV-2感染的癌症患者中,整个COVID-19大流行期间存在治疗延迟或中断的种族与民族不平等,且不同病毒波次间差异模式不同。

这项横断面研究利用美国临床肿瘤学会COVID-19肿瘤登记数据(2020年4月至2022年9月),纳入69家美国实践机构中4054例合并SARS-CoV-2感染的癌症患者,评估不同疫情波次中癌症治疗延迟或中断(TDD,定义为任何癌症治疗推迟超过2周或取消且无重新安排计划)的种族与民族差异。多变量Poisson回归显示,大流行第一年(第三波)非西班牙裔黑人和西班牙裔或拉丁裔患者TDD风险高于非西班牙裔白人;到2022年,非西班牙裔亚裔患者风险升高而非西班牙裔美国印第安人或阿拉斯加原住民患者风险降低。作者认为这些不平等可能对美国少数族裔成年人的癌症死亡率产生下游不良影响。

要点

  • TDD定义为任何癌症治疗推迟超过2周或取消且无重新安排计划;4054例中1853例(45.7%)发生TDD。
  • 大流行第一年第三波,非西班牙裔黑人(aPR 1.56;95%CI 1.31-1.85)和西班牙裔或拉丁裔(aPR 1.35;95%CI 1.13-1.62)患者TDD风险高于非西班牙裔白人。
  • 到2022年,非西班牙裔亚裔患者TDD风险高于非西班牙裔白人(aPR 1.51;95%CI 1.08-2.12)。
  • 到2022年,非西班牙裔美国印第安人或阿拉斯加原住民患者TDD风险低于非西班牙裔白人(aPR 0.37;95%CI 0.16-0.89)。
  • 整个大流行期间基于病例激增的种族与民族不平等差异随总体TDD下降而随时间减小。

适用人群与场景

  • 美国69家实践机构中合并SARS-CoV-2感染的癌症患者,数据来自美国临床肿瘤学会COVID-19肿瘤登记(2020年4月至2022年9月)。
  • 分析聚焦于在SARS-CoV-2诊断时计划接受药物治疗(3682例,90.8%)、放疗(382例,9.4%)、手术(218例,5.4%)或移植(30例,0.7%)的患者。

诊断标准与关键阈值

  • TDD定义为任何癌症治疗推迟超过2周或取消且无重新安排计划。
  • SARS-CoV-2重症定义为死亡、住院、重症监护室入住或机械通气。

研究设计与关键结果

  • 横断面研究,纳入4054例合并SARS-CoV-2感染的癌症患者:美国印第安人或阿拉斯加原住民143例(3.5%)、亚裔176例(4.3%)、黑人或非裔美国人517例(12.8%)、西班牙裔或拉丁裔469例(11.6%)、白人2747例(67.8%);女性2403例(59.3%);50-64岁1419例(35.1%);≥65岁1928例(47.7%)。
  • 1853例(45.7%)发生TDD;多变量Poisson回归调整年龄、性别、体重指数、合并症、癌症类型、癌症范围及SARS-CoV-2严重程度,并考虑诊所内患者非独立性。
  • 第三波:非西班牙裔黑人aPR 1.56(95%CI 1.31-1.85)、西班牙裔或拉丁裔aPR 1.35(95%CI 1.13-1.62),均较非西班牙裔白人更可能发生TDD。
  • 2022年:非西班牙裔亚裔aPR 1.51(95%CI 1.08-2.12),较非西班牙裔白人更可能发生TDD;非西班牙裔美国印第安人或阿拉斯加原住民aPR 0.37(95%CI 0.16-0.89),较非西班牙裔白人更不可能发生TDD。
  • 整个大流行期间基于病例激增的种族与民族不平等差异随总体TDD下降而随时间减小。

证据类型、等级与局限

  • 证据类型:横断面研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些不平等可能对美国少数族裔成年人的癌症死亡率产生下游不良影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Racially and ethnically minoritized US adults were disproportionately impacted by the COVID-19 pandemic and experience poorer cancer outcomes, including inequities in cancer treatment delivery.

OBJECTIVE: To evaluate racial and ethnic disparities in cancer treatment delays and discontinuations (TDDs) among patients with cancer and SARS-CoV-2 during different waves of the COVID-19 pandemic in the United States.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data from the American Society of Clinical Oncology Survey on COVID-19 in Oncology Registry (data collected from April 2020 to September 2022), including patients with cancer also diagnosed with SARS-CoV-2 during their care at 69 US practices. Racial and ethnic differences were examined during 5 different waves of the COVID-19 pandemic in the United States based on case surge (before July 2020, July to November 2020, December 2020 to March 2021, April 2021 to February 2022, and March to September 2022).

EXPOSURES: Race and ethnicity.

MAIN OUTCOMES AND MEASURES: TDD was defined as any cancer treatment postponed more than 2 weeks or cancelled with no plans to reschedule. To evaluate TDD associations with race and ethnicity, adjusted prevalence ratios (aPRs) were estimated using multivariable Poisson regression, accounting for nonindependence of patients within clinics, adjusting for age, sex, body mass index, comorbidities, cancer type, cancer extent, and SARS-CoV-2 severity (severe defined as death, hospitalization, intensive care unit admission, or mechanical ventilation).

RESULTS: A total of 4054 patients with cancer and SARS-CoV-2 were included (143 [3.5%] American Indian or Alaska Native, 176 [4.3%] Asian, 517 [12.8%] Black or African American, 469 [11.6%] Hispanic or Latinx, and 2747 [67.8%] White; 2403 [59.3%] female; 1419 [35.1%] aged 50-64 years; 1928 [47.7%] aged ≥65 years). The analysis focused on patients scheduled (at SARS-CoV-2 diagnosis) to receive drug-based therapy (3682 [90.8%]), radiation therapy (382 [9.4%]), surgery (218 [5.4%]), or transplant (30 [0.7%]), of whom 1853 (45.7%) experienced TDD. Throughout the pandemic, differences in racial and ethnic inequities based on case surge with overall TDD decreased over time. In multivariable analyses, non-Hispanic Black (third wave: aPR, 1.56; 95% CI, 1.31-1.85) and Hispanic or Latinx (third wave: aPR, 1.35; 95% CI, 1.13-1.62) patients with cancer were more likely to experience TDD compared with non-Hispanic White patients during the first year of the pandemic. By 2022, non-Hispanic Asian patients (aPR, 1.51; 95% CI, 1.08-2.12) were more likely to experience TDD compared with non-Hispanic White patients, and non-Hispanic American Indian or Alaska Native patients were less likely (aPR, 0.37; 95% CI, 0.16-0.89).

CONCLUSIONS AND RELEVANCE: In this cross-sectional study of patients with cancer and SARS-CoV-2, racial and ethnic inequities existed in TDD throughout the pandemic; however, the disproportionate burden among racially and ethnically minoritized patients with cancer varied across SARS-CoV-2 waves. These inequities may lead to downstream adverse impacts on cancer mortality among minoritized adults in the United States.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Islam JY, Hathaway CA, Hume E, et al. Racial and Ethnic Inequities in Cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2. JAMA Netw Open. 2024. PMID: 38767916. doi:10.1001/jamanetworkopen.2024.12050

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。